DELORIS E. KOZIOL, MT.; PAUL V. HOLLAND, M.D.; DAVID W. ALLING, M.D.; JACQUELINE C. MELPOLDER, M.T.; RACHEL E. SOLOMON, M.H.S.; ROBERT H. PURCELL, M.D.; LENITA M. HUDSON, M.T.; FRANCES J. SHOUP, R.N.; HENRY KRAKAUER, M.D.; HARVEY J. ALTER, M.D.
The relationship between the presence of antibody to hepatitis B core antigen (anti-HBc) in donor blood and the development of hepatitis in recipients of that blood was studied in 6293 blood donors and 481 recipients who were followed for 6 to 9 months after transfusion. Of 193 recipients of at least 1 unit of blood positive for anti-HBc, 23 (11.9%) developed non-A, non-B hepatitis compared with 12 (4.2%) of 288 recipients of only anti-HBc-negative blood (p < 0.001). Donor anti-HBc status was not significantly associated with the development of hepatitis B in the recipient and was negatively associated with the development of cytomegalovirus hepatitis. The relationship of donor anti-HBc status and the development of non-A, non-B hepatitis in the recipient was independent of transfusion volume and elevated donor transaminase level. Although 88% of anti-HBc-positive blood units were not associated with recipient non-A, non-B hepatitis, calculation of maximal corrected efficacy predicted that exclusion of anti-HBc-positive donors might have prevented 43% of the cases of non-A, non-B hepatitis with a donor loss of 4%. Because of the serious chronic consequences of non-A, non-B hepatitis, surrogate tests for non-A, non-B virus carriers must be seriously considered.
KOZIOL DE, HOLLAND PV, ALLING DW, et al. Antibody to Hepatitis B Core Antigen as a Paradoxical Marker for Non-A, Non-B Hepatitis Agents in Donated Blood. Ann Intern Med. 1986;104:488–495. doi: 10.7326/0003-4819-104-4-488
Download citation file:
Published: Ann Intern Med. 1986;104(4):488-495.
Gastroenterology/Hepatology, Infectious Disease, Liver Disease.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use